8,148 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Global Retirement Partners LLC

Key Points

• Global Retirement Partners LLC purchased 8,148 shares of Thermo Fisher Scientific worth approximately $4.1 million in the second quarter. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported quarterly revenue of $11.99 billion and earnings of $6.03 per share, exceeding analyst expectations; revenue increased 10.5% year over year. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $619.41.
• Shares opened at $586.62, while the company declared a quarterly dividend of $0.47 per share, representing a 0.3% annualized yield. Recent insider activity was notably negative, with insiders selling 52,053 shares worth about $30.6 million over three months.

Global Retirement Partners LLC purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 8,148 shares of the medical research company's stock, valued at approximately $4,085,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in TMO. Legacy Wealth Managment LLC ID boosted its holdings in Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after purchasing an additional 22 shares during the last quarter. Allied Private Wealth LLC purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $26,000. High Note Wealth LLC boosted its stake in shares of Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after buying an additional 29 shares during the last quarter. Swiss RE Ltd. acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $28,000. Finally, JPL Wealth Management LLC purchased a new position in Thermo Fisher Scientific during the third quarter valued at approximately $28,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on TMO shares. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a research report on Friday, April 24th. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a "market perform" rating and a $520.00 target price for the company. Barclays raised their price target on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a research report on Friday, July 24th. Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a research report on Friday, May 8th. Finally, Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a research note on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $619.41.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $586.62 on Tuesday. The firm has a 50-day simple moving average of $531.72 and a 200-day simple moving average of $508.48. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $216.90 billion, a price-to-earnings ratio of 31.56, a price-to-earnings-growth ratio of 2.39 and a beta of 0.84. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the prior year, the firm earned $4.28 EPS. Thermo Fisher Scientific's quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.11%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of the company's stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This represents a 12.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Lisa P. Britt sold 5,850 shares of Thermo Fisher Scientific stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $580.00, for a total value of $3,393,000.00. Following the transaction, the vice president owned 14,784 shares in the company, valued at approximately $8,574,720. This represents a 28.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 52,053 shares of company stock valued at $30,643,589 in the last three months. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source